FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3213468071> ?p ?o ?g. }

• W3213468071 endingPage "251" @default.
• W3213468071 startingPage "239" @default.
• W3213468071 abstract "IntroductionCoronavirus disease 2019 resulted in a 30% mortality rate in patients with thoracic cancer. Given that patients with cancer were excluded from serum antisevere acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccine registration trials, it is still unknown whether they would develop a protective antispike antibody response after vaccination. This prospective vaccine monitoring study primarily aimed to assess humoral responses to the SARS-CoV-2 vaccine in patients with thoracic cancer.MethodsSARS-CoV-2–spike antibodies were measured using the Abbot Architect SARS-CoV-2 immunoglobulin G immunoassay before the first injection of BNT162b2 mRNA vaccine, at week 4, and 2 to 16 weeks after the second vaccine dose administration. The factors associated with antibody response were analyzed.ResultsOverall, 306 patients, with a median age of 67.0 years (interquartile range: 58–74), were vaccinated. Of these, 283 patients received two vaccine doses at 28-day intervals. After a 6.7-month median follow-up, eight patients (2.6%) contracted proven symptomatic SARS-CoV-2 infection, with rapid favorable evolution. Of the 269 serologic results available beyond day 14 after the second vaccine dose administration, 17 patients (6.3%) were still negative (<50 arbitrary units/mL, whereas 34 (11%) were less than 300 arbitrary units/mL (12.5th percentile). In multivariate analysis, only age (p < 0.01) and long-term corticosteroid treatment (p = 0.01) were significantly associated with a lack of immunization. A total of 30 patients received a third vaccine dose, with only three patients showing persistently negative serology thereafter, whereas the others exhibited clear seroconversion.ConclusionsSARS-CoV2 vaccines were found to be efficient in patients with thoracic cancer, most of them being immunized after two doses. A third shot given to 1% of patients with persistent low antibody titers resulted in an 88% immunization rate." @default.
• W3213468071 created "2021-11-22" @default.
• W3213468071 creator A5005901060 @default.
• W3213468071 creator A5020430327 @default.
• W3213468071 creator A5028897044 @default.
• W3213468071 creator A5029441961 @default.
• W3213468071 creator A5034539474 @default.
• W3213468071 creator A5035784421 @default.
• W3213468071 creator A5047124634 @default.
• W3213468071 creator A5049014743 @default.
• W3213468071 creator A5056853165 @default.
• W3213468071 creator A5059602594 @default.
• W3213468071 creator A5063103135 @default.
• W3213468071 creator A5083634011 @default.
• W3213468071 creator A5088096181 @default.
• W3213468071 creator A5091105156 @default.
• W3213468071 creator A5091466060 @default.
• W3213468071 date "2022-02-01" @default.
• W3213468071 modified "2023-10-18" @default.
• W3213468071 title "Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses" @default.
• W3213468071 cites W2142549578 @default.
• W3213468071 cites W2147699808 @default.
• W3213468071 cites W2742299198 @default.
• W3213468071 cites W3012860910 @default.
• W3213468071 cites W3015599879 @default.
• W3213468071 cites W3020502835 @default.
• W3213468071 cites W3024270013 @default.
• W3213468071 cites W3031584350 @default.
• W3213468071 cites W3034965161 @default.
• W3213468071 cites W3035256826 @default.
• W3213468071 cites W3043722389 @default.
• W3213468071 cites W3089992861 @default.
• W3213468071 cites W3092131843 @default.
• W3213468071 cites W3092695915 @default.
• W3213468071 cites W3108610942 @default.
• W3213468071 cites W3111021405 @default.
• W3213468071 cites W3111255098 @default.
• W3213468071 cites W3111590711 @default.
• W3213468071 cites W3115737775 @default.
• W3213468071 cites W3128016658 @default.
• W3213468071 cites W3131711260 @default.
• W3213468071 cites W3131762051 @default.
• W3213468071 cites W3132584252 @default.
• W3213468071 cites W3134208712 @default.
• W3213468071 cites W3145657260 @default.
• W3213468071 cites W3153508314 @default.
• W3213468071 cites W3156866359 @default.
• W3213468071 cites W3158078097 @default.
• W3213468071 cites W3158123254 @default.
• W3213468071 cites W3158948419 @default.
• W3213468071 cites W3159505699 @default.
• W3213468071 cites W3163785571 @default.
• W3213468071 cites W3164220019 @default.
• W3213468071 cites W3164652662 @default.
• W3213468071 cites W3164768289 @default.
• W3213468071 cites W3166451371 @default.
• W3213468071 cites W3169034483 @default.
• W3213468071 cites W3173150656 @default.
• W3213468071 cites W3174178131 @default.
• W3213468071 cites W3176215631 @default.
• W3213468071 cites W3176552995 @default.
• W3213468071 cites W3176897911 @default.
• W3213468071 cites W3177181935 @default.
• W3213468071 cites W3179235031 @default.
• W3213468071 cites W3206648736 @default.
• W3213468071 cites W4205483821 @default.
• W3213468071 doi "https://doi.org/10.1016/j.jtho.2021.10.015" @default.
• W3213468071 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8593625" @default.
• W3213468071 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34798306" @default.
• W3213468071 hasPublicationYear "2022" @default.
• W3213468071 type Work @default.
• W3213468071 sameAs 3213468071 @default.
• W3213468071 citedByCount "49" @default.
• W3213468071 countsByYear W32134680712021 @default.
• W3213468071 countsByYear W32134680712022 @default.
• W3213468071 countsByYear W32134680712023 @default.
• W3213468071 crossrefType "journal-article" @default.
• W3213468071 hasAuthorship W3213468071A5005901060 @default.
• W3213468071 hasAuthorship W3213468071A5020430327 @default.
• W3213468071 hasAuthorship W3213468071A5028897044 @default.
• W3213468071 hasAuthorship W3213468071A5029441961 @default.
• W3213468071 hasAuthorship W3213468071A5034539474 @default.
• W3213468071 hasAuthorship W3213468071A5035784421 @default.
• W3213468071 hasAuthorship W3213468071A5047124634 @default.
• W3213468071 hasAuthorship W3213468071A5049014743 @default.
• W3213468071 hasAuthorship W3213468071A5056853165 @default.
• W3213468071 hasAuthorship W3213468071A5059602594 @default.
• W3213468071 hasAuthorship W3213468071A5063103135 @default.
• W3213468071 hasAuthorship W3213468071A5083634011 @default.
• W3213468071 hasAuthorship W3213468071A5088096181 @default.
• W3213468071 hasAuthorship W3213468071A5091105156 @default.
• W3213468071 hasAuthorship W3213468071A5091466060 @default.
• W3213468071 hasBestOaLocation W32134680711 @default.
• W3213468071 hasConcept C119060515 @default.
• W3213468071 hasConcept C121608353 @default.
• W3213468071 hasConcept C126322002 @default.
• W3213468071 hasConcept C159654299 @default.
• W3213468071 hasConcept C188816634 @default.

• next